GB Patent

GB2588576A — Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease

Assigned to GW Research Ltd · Expires 2021-05-05 · 5y expired

What this patent protects

Tetrahydrocannabivarin (THCV) for use in the treatment of dyskinesia associated with Parkinson’s disease is provided. Preferably the dose of THCV is between 0.1 and 1000mg/kg day. The THCV may be botanically derived highly purified THCV or may be synthetic THCV.

USPTO Abstract

Tetrahydrocannabivarin (THCV) for use in the treatment of dyskinesia associated with Parkinson’s disease is provided. Preferably the dose of THCV is between 0.1 and 1000mg/kg day. The THCV may be botanically derived highly purified THCV or may be synthetic THCV.

Drugs covered by this patent

Patent Metadata

Patent number
GB2588576A
Jurisdiction
GB
Classification
—
Expires
2021-05-05
Drug substance claim
No
Drug product claim
No
Assignee
GW Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.